Phase II open-label non-randomized multicenter clinical trial of trametinib for dogs with histiocytic sarcoma
New university findings highlight potential implications for dogs, oncology, and veterinary practice.
This study investigates a new anti-cancer drug, trametinib, that specifically targets growth signals found in cancer cells of dogs.
Phase II open-label non-randomized multicenter clinical trial of trametinib for dogs with histiocytic sarcoma | College of Veterinary Medicine at MSU Support the College of Veterinary Medicine Search Tool Clinical Trials Select Chronic Kidney Disease in Cats Direct Comparison of CHOP and LOPP Chemotherapy and Genomic Analysis for Naïve T Cell Lymphoma in Client-owned Dogs FAQs with Dr.
Histiocytic sarcoma is an aggressive cancer in dogs.
Even with treatment, most of the time the disease will spread quickly.
Response rates to current treatments are usually poor.
Trametinib is FDA-approved for use in people, and our previous studies have identified a safe dose for dogs.
This study will determine the anti-tumor effect of trametinib in dogs diagnosed with histiocytic sarcoma.
We hope that this new treatment, which is still experimental in dogs, will decrease the size of the cancer, improve the patients' outcomes, and increase their life expectancy.
Additionally, the study will test whether markers in the cancer cells’ genes can predict the response to treatment.
This information could be used in the future to help select those dogs that are more likely to respond positively to treatment.
This study is supported by The Bernese Mountain Dog Club of America .
The report adds to ongoing university-led research relevant to veterinary medicine, animal health, and clinical decision-making.
Source university website: Michigan State University College of Veterinary Medicine
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment